Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ALXO vs GNLX — Stock Comparison
Compare ALXO and GNLX side-by-side on StoQuant: ALXO Q-Score 31 vs GNLX 49; analyst signal 65 vs 73. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ALXO — ALX Oncology Holdings Inc. · Health Care · market cap $162M · Q-Score verdict Sell (31.0, grade D) · analyst signal 65/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 95/100, valuation 70/100 · weakest signals: analyst consensus 46/100, technicals 18/100. Full ALXO research.
- GNLX — Genelux Corporation · Health Care · market cap $90M · Q-Score verdict Hold (49.0, grade C) · analyst signal 73/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 97/100, analyst consensus 65/100 · weakest signals: technicals 35/100. Full GNLX research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ALXO research · GNLX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.